menu
    • menu
    [{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Marc Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"S007-867","moa":"Collagen induced aggregation","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ Marc Laboratories","highestDevelopmentStatusID":"5","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ Marc Laboratories"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ CSIR-Indian Institute of Chemical Technology","highestDevelopmentStatusID":"8","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ CSIR-Indian Institute of Chemical Technology"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"||Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ LAXAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ LAXAI Life Sciences"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"AIIMS","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"BGR-34","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ CSIR-Indian Institute of Chemical Technology","highestDevelopmentStatusID":"15","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ CSIR-Indian Institute of Chemical Technology"}]

    Find Clinical Drug Pipeline Developments & Deals by CSIR-Indian Institute of Chemical Technology

    Menu

    CSIR-Indian Institute of Chemical Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S007-867

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Marc Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CSIR-CDRI Signs Agreement with Marc Labs to Develop Drug for Heart Attack and Stroke

                            Details : The agreement has been signed for the development of a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 12, 2021

                            Lead Product(s) : S007-867

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Marc Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine,Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : LAXAI Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CSIR in Partnership with Laxai Life Sciences has received Regulatory Approval to Begin Clinical Trials on Covi...

                            Details : CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 pati...

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 12, 2021

                            Lead Product(s) : Colchicine,Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : LAXAI Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : LAXAI Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins

                            Details : The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2021

                            Lead Product(s) : Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : LAXAI Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed

                            CSIR-Indian Institute of Chemical Technology

                            India arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BGR-34,Glibenclamide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIIMS Researchers Find Ayurvedic-Allopathic Combo BGR-34 & Glibenclamide in Controlling Diabetes

                            Details : In the Animal experimental study, doctors have found that the pace of diabetes growth can be halted if allopathic drug is integrated with BGR-34, a herbal formulation enriched with antioxidant properties which stops bad cholesterol from accumulating in t...

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 03, 2021

                            Lead Product(s) : BGR-34,Glibenclamide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth